Company: LGNZZ
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0000886163-25-000051
Chunk: 15

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-08-08
Form: 10-Q
Item: Item 1
Chunk 15
---
 (29)54,410      Corporate notes/bonds17,138 13 (11)17,140      Corporate equity securities7,828 2,077 (1,915)7,990      Certificates of Deposit6,741 1 (1)6,741 $150,728 $2,095 $(1,972)150,851       Viking common stock26,500 Total short-term investments$177,351 December 31, 2024     U.S. Treasuries$78,442 $19 $(13)$78,448      Commercial paper23,483 5 (6)23,482      Certificates of Deposit22,812 12 (4)22,820      Corporate notes/bonds15,496 21 (8)15,509      Corporate equity securities9,954 — (6,595)3,359 $150,187 $57 $(6,626)143,618      Viking common stock40,240 Total short-term investments$183,858 

13

During the three and six months ended June 30, 2025, we did not sell any shares of Viking common stock. During the six months ended June 30, 2024, we sold 0.7 million shares of Viking common stock and recognized a realized gain of $60.0 million in total. We did not sell any shares of Viking common stock during the three months ended June 30, 2024.Gain (loss) from short-term investments in our condensed consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities.Allowances are recorded for available-for-sale debt securities with unrealized losses. This limits the amount of credit losses that can be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The provisions of the credit losses standard did not have a material impact on our available-for-sale debt securities during the three and six months ended June 30, 2025 and 2024.The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):June 30, 2025Amortized CostFair ValueWithin one year$136,824 $136,780 After